NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call
January 22, 2021 11:05 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of...
NeuroMetrix Reports Q3 2020 Financial Results
October 22, 2020 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading...
NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call
October 15, 2020 11:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on...
NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
September 22, 2020 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store. Quell is a...
NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
September 21, 2020 13:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No....
NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
September 04, 2020 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be...
NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
September 01, 2020 13:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of...
NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
August 20, 2020 14:11 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of...
Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free
August 10, 2020 10:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain (available here) and provided an update on how Quell technology...
NeuroMetrix Reports Q2 2020 Financial Results
July 23, 2020 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading...